Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 16/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310098 | 0.92 | BDKRB1 (0.40) | BDKRB1HSD17B10CYP3A4ALDH1A1 | |
| SCHEMBL3408124 | 0.92 | BDKRB1 (0.41) | BDKRB1HSD17B10TSHRHIF1AALDH1A1 | |
| SCHEMBL3314535 | 0.92 | BDKRB1 (0.39) | BDKRB1HSD17B10CYP3A4ALDH1A1 | |
| SCHEMBL3314543 | 0.92 | BDKRB1 (0.39) | BDKRB1HSD17B10CYP3A4ALDH1A1 | |
| SCHEMBL3316351 | 0.90 | BDKRB1 (0.40) | BDKRB1HSD17B10TSHRHIF1A | |
| SCHEMBL3316346 | 0.90 | BDKRB1 (0.40) | BDKRB1HSD17B10TSHRHIF1A | |
| SCHEMBL12694732 | 0.90 | HSD17B10 (0.35) | HSD17B10TSHRHIF1ACYP3A4ALDH1A1 | |
| SCHEMBL12694771 | 0.89 | NPC1 (0.36) | BDKRB1TSHRCYP3A4ALDH1A1KMT2A | |
| SCHEMBL3829718 | 0.89 | ALDH1A1 (0.41) | BDKRB1HSD17B10TSHRHIF1AALDH1A1 | |
| SCHEMBL3312085 | 0.88 | BDKRB1 (0.37) | BDKRB1TSHRCYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278319-B2 | Substituted spiroamine compounds | GRUENENTHAL GMBH (DE) | 2012-10-02 | — | — | US | claimed |
| US-8278319-B2 | Substituted spiroamine compounds | GRUENENTHAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| WO-2010049146-A1 | SUBSTITUTED SPIROAMINES | Grünenthal GmbH (DE) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113417-A1 | Substituted Spiroamine Compounds | BDKRB1, BDKRB2, REN | BDKRB1 1/4885HSD17B10 3502/4885TSHR 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.